Resistance evolution in HIV — Modeling when to intervene

The treatment of HIV is complicated by the evolution of antiviral drug resistant virus and the limited availability of antigenically independent antiviral regimens. The consequences to the patient of successive virological failures is such that many strategies to minimize the occurrence of such failures are being investigated. In this paper, a Markov chain-based model of virological failure is introduced. This model considers sequential failure events, and differentiates between several modes of virological failure. This model is then used to evaluate the resistance- targeted interventions by means of testing the impact of a viral load preconditioning strategy on total treatment regimen longevity in HIV patients. It is shown that a proposed intervention targeting pre-existing resistance has the potential to increase the expected time to three sequential virological failures by an average of 3.3 years per patient. When combined with an intervention targeting patient compliance, the total potential increase in the time to three sequential virological failures is as high as 11.2 years. The impact on patient and public health is discussed.

[1]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[2]  Richard D Moore,et al.  Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Gruchalla.  Understanding drug allergies. , 2000, The Journal of allergy and clinical immunology.

[4]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[5]  F. Parazzini,et al.  Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study , 2000, Journal of acquired immune deficiency syndromes.

[6]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[7]  S. Deeks.  Determinants of virological response to antiretroviral therapy: implications for long-term strategies. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Ho,et al.  HIV-1 dynamics in vivo: implications for therapy , 2003, Nature Reviews Microbiology.

[9]  Yangxin Huang,et al.  Long-term HIV dynamic models incorporating drug adherence and resistance to treatment for prediction of virological responses , 2008, Comput. Stat. Data Anal..

[10]  P. Volberding,et al.  Antiretroviral therapy and management of HIV infection , 2010, The Lancet.

[11]  Libin Rong,et al.  Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. , 2009, Mathematical biosciences.

[12]  S. Lawn,et al.  Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings. , 2006, The Lancet. Infectious diseases.

[13]  F. Parazzini,et al.  Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. , 2000 .

[14]  H. Chueh,et al.  Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic , 2007, Journal of acquired immune deficiency syndromes.

[15]  R. Stephenson.  A and V , 1962, The British journal of ophthalmology.

[16]  S. Broder,et al.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.

[17]  Patricia Buendia,et al.  A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance , 2009, Bioinform..

[18]  W. Marsden.  I and J , 2012 .

[19]  D. Ho,et al.  Viral Counts Count in HIV Infection , 1996, Science.

[20]  A. Haase,et al.  Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. , 1999, Annual review of immunology.

[21]  Sonya J Snedecor,et al.  Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression , 2005, Bulletin of mathematical biology.

[22]  Mark S Roberts,et al.  Using Mechanistic Models to Simulate Comparative Effectiveness Trials of Therapy and to Estimate Long-term Outcomes in HIV Care , 2010, Medical care.

[23]  R. Hays,et al.  A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.

[24]  L. M. Mansky,et al.  HIV mutagenesis and the evolution of antiretroviral drug resistance. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[25]  Steven M. Shechter,et al.  Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. , 2006, The Journal of antimicrobial chemotherapy.

[26]  Michael J Piovoso,et al.  Controlling the Evolution of Resistance. , 2011, Journal of process control.

[27]  Marco Mancini,et al.  Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study , 2010, PloS one.

[28]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[29]  Libin Rong,et al.  Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility. , 2007, Journal of theoretical biology.

[30]  Michael J. Piovoso,et al.  Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy , 2011, PloS one.

[31]  Michael J. Piovoso,et al.  A generalized multi-strain model of HIV evolution with implications for drug-resistance management , 2009, 2009 American Control Conference.

[32]  S. Bonhoeffer,et al.  Stochastic Interplay between Mutation and Recombination during the Acquisition of Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[33]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[34]  T. Kunkel,et al.  Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. , 1989, The Journal of biological chemistry.

[35]  Francoise F Giguel,et al.  Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. , 2003, AIDS.

[36]  Mark S Roberts,et al.  Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[37]  R. Zurakowski,et al.  A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment , 2008, 2008 American Control Conference.

[38]  U. Gerlach.  Interruption of antiretroviral treatment in HIV-infected children , 2004 .

[39]  K. Crandall,et al.  The causes and consequences of HIV evolution , 2004, Nature Reviews Genetics.

[40]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[41]  Steven G. Deeks,et al.  The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy , 2009, PloS one.

[42]  J. Miro,et al.  Optimal Timing and Best Antiretroviral Regimen in Treatment-naive HIV-Infected Individuals with Advanced Disease , 2007, Journal of acquired immune deficiency syndromes.

[43]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[44]  J. Montaner,et al.  Adverse effects of antiretroviral therapy for HIV infection. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[45]  A. Welte,et al.  Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations , 2008, Theoretical Biology and Medical Modelling.

[46]  Joly,et al.  New trends in antiretroviral therapy for HIV infection. , 2000, European journal of internal medicine.

[47]  Ryan Zurakowski,et al.  Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching , 2011, 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[48]  S Bonhoeffer,et al.  Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Montaner,et al.  Management of HIV-infected patients with multidrug-resistant virus , 2004, Current HIV/AIDS reports.

[50]  H. Sørensen,et al.  Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals , 2005, AIDS.